Cookies help us to understand how you use our website so that we can provide you with the best experience when you are on our site. To find out more, read our privacy policy and cookie policy.
Manage Cookies
A cookie is information stored on your computer by a website you visit. Cookies often store your settings for a website, such as your preferred language or location. This allows the site to present you with information customized to fit your needs. As per the GDPR law, companies need to get your explicit approval to collect your data. Some of these cookies are ‘strictly necessary’ to provide the basic functions of the website and can not be turned off, while others if present, have the option of being turned off. Learn more about our Privacy and Cookie policies. These can be managed also from our cookie policy page.
Strictly necessary cookies(always on):
Necessary for enabling core functionality. The website cannot function properly without these cookies. This cannot be turned off. e.g. Sign in, Language
Analytics cookies:
Analytical cookies help us to analyse user behaviour, mainly to see if the users are able to find and act on things that they are looking for. They allow us to recognise and count the number of visitors and to see how visitors move around our website when they are using it. Tools used: Google Analytics
Social media cookies:
We use social media cookies from Facebook, Twitter and Google to run Widgets, Embed Videos, Posts, Comments and to fetch profile information.
Reducing pain for people with cancer that has spread to the spine
Share Reducing pain for people with cancer that has spread to the spine on FacebookShare Reducing pain for people with cancer that has spread to the spine on TwitterShare Reducing pain for people with cancer that has spread to the spine on LinkedinEmail Reducing pain for people with cancer that has spread to the spine link
Consultation has concluded
We would like to invite people with experience of treatment for cancer that has spread to their spine, or relatives of patients with such experience to join this discussion forum.
What is SENSE? A randomised trial to evaluate whether targeted radiotherapy is better than conventional radiotherapy for reducing pain for people with cancer that has spread to the spine.
Chief Investigator (Lead Clinician): Dr Merina Ahmed, Statistical/ Methodology Lead: Dr Fay Cafferty
We would like to find out if people are supportive of the idea of the trial. We would also like to discuss what they think are the most important questions to try and answer within the trial. We will use their feedback to help develop the trial for a funding application in Summer 2023.
No experience of clinical research or patient and public involvement in research is required. We will provide background information and any other support people may need to be able to contribute.
The forum will be held online on 20th July 2023 from 12 - 1.30pm. The research team will present the current design of the trial and invite all participants to offer their input and opinions on the design and important questions and aspects from a patient’s perspective.
The trial is being developed by the Clinical Trials and Statistics Unit at The Institute of Cancer Research, a college of the University of London.
We would like to invite people with experience of treatment for cancer that has spread to their spine, or relatives of patients with such experience to join this discussion forum.
What is SENSE? A randomised trial to evaluate whether targeted radiotherapy is better than conventional radiotherapy for reducing pain for people with cancer that has spread to the spine.
Chief Investigator (Lead Clinician): Dr Merina Ahmed, Statistical/ Methodology Lead: Dr Fay Cafferty
We would like to find out if people are supportive of the idea of the trial. We would also like to discuss what they think are the most important questions to try and answer within the trial. We will use their feedback to help develop the trial for a funding application in Summer 2023.
No experience of clinical research or patient and public involvement in research is required. We will provide background information and any other support people may need to be able to contribute.
The forum will be held online on 20th July 2023 from 12 - 1.30pm. The research team will present the current design of the trial and invite all participants to offer their input and opinions on the design and important questions and aspects from a patient’s perspective.
The trial is being developed by the Clinical Trials and Statistics Unit at The Institute of Cancer Research, a college of the University of London.
